Pharmaceuticals & Biologics

Overview

By bringing innovative products to market, pharmaceutical companies help people live longer, higher-quality lives — and our attorneys and other professionals are dedicated to facilitating that progress. Our professionals include former in-house counsel and senior executives for some of the world’s largest pharmaceutical companies, as well as an interdisciplinary team of experienced attorneys and professionals who provide regulatory, transactional, litigation, intellectual property and government affairs services tailored to the pharmaceutical industry. We help clients tackle business and financing pressures, regulatory scrutiny and litigation threats on a national and international scale. We have steered global pharma companies through multibillion-dollar transactions and helped international drug manufacturers accelerate drug development through creative joint ventures. Our IP attorneys work to patent your inventions in countries around the globe; shield your brands through trademark policing and anti-counterfeiting strategies; and negotiate commercial, licensing and other strategic agreements — freeing you to focus on product development and innovation. We serve as outside general counsel for regulatory compliance matters and support on all interactions with the Food and Drug Administration and other regulatory parties, including inspections, investigations and enforcement. And when disputes occur, our trial lawyers are there to handle any issue. Whether enforcing your rights or defending against alleged wrongdoing, including in product liability litigation, our team of skilled trial attorneys is ready to represent you in high-stakes, bet-the-company litigation every day.

Insights & Events

Latest

最新 October 2025

FDA’s Prioritization Pilot Providing Faster Review When Generic Drugs — APIs or Finished Products — Are Produced Domestically

Could Adjusting Your Supply Chains Allow You to Take Advantage of ANDA Review Prioritization?
3 min read
最新 August 2025

Effects of the One Big Beautiful Bill Act on Health Care and Pharma; and More

Biopharma & Medical Devices Briefing
7 min read
媒体报道 June 2025

Bench & Bar of Minnesota Highlights New MSBA President Tom Pack’s Approach to Leadership

1 min read
Press Release June 2025

Faegre Drinker Strengthens Nationwide Product Liability & Mass Torts Practice, Adding Medical Device Litigator Dan Smulian in New York

3 min read
Speaking Engagement Recap May 16, 2025

AI Policy and the New Administration: Implications for FDA-Regulated Industries

2025 FDLI Annual Conference
1 min read
最新 May 2025

Is This the Death Knell of Strict Liability Crimes?

The Impact of President Trump’s May 9, 2025, Executive Order on Regulatory Criminal Offenses & FDCA Enforcement
10 min read
媒体报道 May 2025

Barrett Tenbarge Provides Insights on FDA Staffing Cuts for Chemical & Engineering News

1 min read
最新 May 2025

HHS and FDA Launch RFI on Deregulatory Plan — A Key Opportunity to Shape Health and Food Policy

Submissions Through Regulations.gov Due July 14, 2025
4 min read
Press Release May 2025

Faegre Drinker Grows Customs & International Trade Practice in Washington, D.C., Welcoming Prominent Trade Enforcement Partner Daniel Wilson

3 min read
Speaking Engagement Recap November 20, 2024

Managed Care, Enforcement and Compliance

Healthcare Enforcement Compliance Conference
1 min read
Insights
最新 October 2025

FDA’s Prioritization Pilot Providing Faster Review When Generic Drugs — APIs or Finished Products — Are Produced Domestically

Could Adjusting Your Supply Chains Allow You to Take Advantage of ANDA Review Prioritization?
3 min read
最新 August 2025

Effects of the One Big Beautiful Bill Act on Health Care and Pharma; and More

Biopharma & Medical Devices Briefing
7 min read
媒体报道 June 2025

Bench & Bar of Minnesota Highlights New MSBA President Tom Pack’s Approach to Leadership

1 min read
最新 May 2025

Is This the Death Knell of Strict Liability Crimes?

The Impact of President Trump’s May 9, 2025, Executive Order on Regulatory Criminal Offenses & FDCA Enforcement
10 min read
媒体报道 May 2025

Barrett Tenbarge Provides Insights on FDA Staffing Cuts for Chemical & Engineering News

1 min read
最新 May 2025

HHS and FDA Launch RFI on Deregulatory Plan — A Key Opportunity to Shape Health and Food Policy

Submissions Through Regulations.gov Due July 14, 2025
4 min read
发表文章 May 2025

How do we put Meaning Into Meaningful Benefit? Perspectives From the Lived Experience

2 min read
最新 May 2025

FDA Identifies Data Quality and Study Conduct Concerns With Raptim Research and Requires Sponsors to Submit Replacement Study Data

Reminder of Importance of Adequately Vetting Contract Research Organizations
5 min read
May 2025

The Hidden Dangers of Alternative Funding Programs

1 min read
最新 April 2025

Data Security Program, Medicare Advantage, Colorado Insurance Requirements & More

Artificial Intelligence Briefing
8 min read

Meet The Team

Meet The Team